Search clinical trials for: TKI

Total 503 results

xuna
Nanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaborators

Withdrawn

Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT (Case-Only)

Prophylactic HQP1351 Therapy | Third Generation TKI

China
Intergroupe Francophone de Cancerologie Thoracique
Novartis

Completed

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) (CapmATU)

Non Small Cell Lung Cancer | MET Alterations | METex14 Mutations

France
Novartis Pharmaceuticals

Completed

Study Conducted Among Patients With CML

Chronic Myeloid Leukemia

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Blueprint Medicines Corporation

Completed

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

GIST

United States, Korea, Republic of, Netherlands, China, France, Spain, Italy, Belgium, United Kingdom, Singapore, Australia, Canada, Germany, Sweden, Hungary, Austria, Czechia, Poland
Neurological Associates of West Los Angeles
Pfizer

Enrolling by invitation

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Dementia | Mild Cognitive Impairment

United States
Yunfei Yuan

Completed

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT

Hepatocellular Carcinoma

China
ETOP IBCSG Partners Foundation
Hoffmann-La Roche; AstraZeneca

Active, not recruiting

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) (BOOSTER)

Non Small Cell Lung Cancer Metastatic

Ireland, Singapore, Spain, Switzerland, Korea, Republic of, Netherlands
ETOP IBCSG Partners Foundation
Biodesix, Inc.

Completed

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. (EMPHASIS)

Carcinoma, Non-Small-Cell Lung

Ireland, Switzerland, Denmark, Spain, United Kingdom, Belgium, Hungary, Greece, Israel, Austria, Italy, Netherlands
National Taiwan University Hospital

Completed

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Tumor Progression | EGFR Exon 19 Mutation

Taiwan
Ocular Therapeutix, Inc.

Active, not recruiting

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Neovascular Age-related Macular Degeneration

Australia
Roswell Park Cancer Institute
Novartis

Completed

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Unspecified Adult Solid Tumor, Protocol Specific | Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Milton S. Hershey Medical Center

Terminated

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia, Chronic Phase

United States
Instituto Oncológico Dr Rosell
MFAR; Bioven Europe

Completed

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C (EPICAL)

Carcinoma, Non-Small-Cell Lung

Spain
Blueprint Medicines Corporation

Completed

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Gastrointestinal Stromal Tumors (GIST) | Other Relapsed or Refractory Solid Tumors

United States, United Kingdom, France, Korea, Republic of, Belgium, Germany, Italy, Netherlands, Poland, Spain
Heidelberg University
Novartis Pharmaceuticals; Siemens Healthcare Diagnostics Inc; Institute of Clinical...

Completed

Unifying Advanced Treatment With Advanced Imaging (GISTm3)

Gastrointestinal Stromal Tumor (GIST)

Germany
Bayer

Completed

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease (CADA DIA)

Diabetic Kidney Disease

Spain, Denmark, Bulgaria, Israel, Sweden, Finland, Italy
Assiut University

Active, not recruiting

Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Patients Diagnosed as Chronic Meyloid Leukemia

Egypt
China Medical University Hospital

Completed

Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect

Advanced Lung Adenocarcinoma
Ipsen

Completed

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors (US NIS Cabo)

Locally Advanced or Metastatic Renal Cell Carcinoma

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Withdrawn

Phase I Study of SPH1188-11 in NSCLC (SPH1188-11)

NSCLC Stage IV | NSCLC Stage IIIB

China
European LeukemiaNet

Completed

European Stop Tyrosine Kinase Inhibitor Study (EURO-SKI)

Chronic Myeloid Leukemia

France, Denmark, Norway, Sweden, Czechia, Portugal, Germany, Netherlands, Finland, Greece
Ronald Weigel
AstraZeneca

Terminated

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

Invasive Breast Cancer

United States
Centre Leon Berard
AstraZeneca; Plexxikon

Completed

Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)

Colorectal Cancer | Pancreatic Cancer | Metastatic Cancer | Advanced Cancer

France
Sunnybrook Health Sciences Centre
Merck Sharp & Dohme LLC; Ozmosis Research Inc.

Completed

A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients (OZM-065)

Stage IV Renal Cell Cancer AJCC V7

Canada
Samsung Medical Center

Active, not recruiting

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Non-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase Inhibitors

Korea, Republic of
PrECOG, LLC.
Pfizer

Terminated

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801)

Renal Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Thyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer

United States
Sun Yat-sen University

Completed

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment (EGFR-TKIs)

Non-small Cell Lung Cancer

China
Telios Pharma, Inc.

Completed

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

COVID-19 | Carcinoma | Cancer | Solid Tumor | Sars-CoV2 | Blood Cancer

United States
Association Pour La Recherche des Thérapeutiques...

Completed

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer (BIONIKK)

Clear Cell Metastatic Renal Cell Carcinoma

France
Tongji Hospital
Wuhan University; Hubei Cancer Hospital; Wuhan Union Hospital, China; Renmin Hospital...

Completed

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Amsterdam UMC, location VUmc

Terminated

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients (IRENE)

Lung Cancer

Netherlands
Novartis Pharmaceuticals

Completed

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Melanoma

United States
Korean Cancer Study Group

Completed

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

Hormone Refractory Prostate Cancer

Korea, Republic of
National Cancer Institute (NCI)

Completed

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Medullary Thyroid Cancer (MTC)

United States
Sichuan Provincial People's Hospital

Terminated

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) (Sindas)

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

China
Hanmi Pharmaceutical Company Limited

Terminated

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Non Small Cell Lung Cancer

United States, Australia, Italy, Korea, Republic of, Spain, Germany, Malaysia, Taiwan, Canada, Philippines
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Unknown

Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial

Hepatocellular Carcinoma

China
AstraZeneca

Completed

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT) (REFLECT)

Lung Cancer

Bulgaria
Novartis Pharmaceuticals

Completed

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Excluding Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Cancer | Neoplasm | Tumors

United States
Novartis Pharmaceuticals

Completed

Phase I Dose Escalating Study of TKI258

Advanced Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. (CTKI258A2120)

Advanced Solid Tumors, Excluding Breast Cancer

Netherlands, Switzerland, Denmark, United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Hepatic Impairment | Solid Tumors

Belgium, Germany, Netherlands, Italy, Singapore, United States
Novartis Pharmaceuticals

Completed

Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors

Neoplasms | Cancer | Tumors

United States
Novartis Pharmaceuticals

Completed

Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Netherlands
Novartis Pharmaceuticals

Completed

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Advanced Solid Tumors, Excluding Breast Cancer

United States
Novartis Pharmaceuticals

Completed

A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

Advanced/ Metastatic Renal Cell Cancer

France, Spain, Germany, Taiwan, Netherlands, United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Relapsed or Refractory Multiple Myeloma

United States, Turkey, Canada, Netherlands, Australia, Germany, France

Search clinical trials for: TKI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations